Technical Analysis for CYTK - Cytokinetics, Incorporated
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 65.34 | 0.83% | 0.54 |
Earnings due: May 8
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | 0.83% | |
Doji - Bullish? | Reversal | 0.83% | |
Gapped Down | Weakness | 0.83% | |
Oversold Stochastic | Weakness | 0.83% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.21% | |
Inside Day | Range Contraction | -2.21% | |
Oversold Stochastic | Weakness | -2.21% | |
Stochastic Buy Signal | Bullish | -0.35% |
Alert | Time |
---|---|
Possible NR7 | about 13 hours ago |
60 Minute Opening Range Breakdown | about 16 hours ago |
60 Minute Opening Range Breakout | about 17 hours ago |
Rose Above Previous Day's High | about 17 hours ago |
Up 1% | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Cytokinetics, Incorporated Description
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Clinical Development Neuroscience Heart Failure Dysfunction Product Design Orphan Drug Amyotrophic Lateral Sclerosis Cytokine Nervous System Drug Design Molecule Therapeutics Treatment Of Heart Failure Medicinal Product
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 110.0 |
52 Week Low | 25.98 |
Average Volume | 2,040,882 |
200-Day Moving Average | 51.25 |
50-Day Moving Average | 70.08 |
20-Day Moving Average | 69.67 |
10-Day Moving Average | 66.83 |
Average True Range | 2.91 |
RSI (14) | 40.48 |
ADX | 21.76 |
+DI | 13.99 |
-DI | 23.23 |
Chandelier Exit (Long, 3 ATRs) | 66.97 |
Chandelier Exit (Short, 3 ATRs) | 72.64 |
Upper Bollinger Bands | 76.12 |
Lower Bollinger Band | 63.22 |
Percent B (%b) | 0.16 |
BandWidth | 18.51 |
MACD Line | -1.36 |
MACD Signal Line | -0.80 |
MACD Histogram | -0.5628 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 67.77 | ||||
Resistance 3 (R3) | 67.76 | 66.94 | 67.37 | ||
Resistance 2 (R2) | 66.94 | 66.32 | 66.95 | 67.23 | |
Resistance 1 (R1) | 66.14 | 65.94 | 66.54 | 66.15 | 67.09 |
Pivot Point | 65.32 | 65.32 | 65.52 | 65.33 | 65.32 |
Support 1 (S1) | 64.52 | 64.70 | 64.92 | 64.53 | 63.59 |
Support 2 (S2) | 63.70 | 64.32 | 63.71 | 63.45 | |
Support 3 (S3) | 62.90 | 63.70 | 63.32 | ||
Support 4 (S4) | 62.91 |